Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q16161440> ?p ?o }
Showing triples 1 to 38 of
38
with 100 triples per page.
- Q16161440 subject Q16780075.
- Q16161440 subject Q20930837.
- Q16161440 subject Q7110183.
- Q16161440 subject Q8760180.
- Q16161440 abstract "Green Cross [녹십자; 綠十字] (KRX: 006280) is a biopharmaceutical company headquartered in Yongin, South Korea.Green Cross specializes in the development and commercialization of vaccines, plasma-derivatives, recombinant proteins, and therapeutic antibodies for use in the fields of oncology and infectious disease.Green Cross was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971. The company is engaged in research, development, manufacturing and sales of medicine and medical supplies, etc. Green Cross notably developed "Hepavax B", the world’s 3rd Hepatitis B vaccine in 1983, the world's first vaccine “Hantavax” against epidemic hemorrhagic fever in 1988, the world’s 2nd varicella vaccine in 1995, "Greengene", the world’s 4th recombinant drug for hemophilia A and the world's second treatment of Hunter syndrome “Hunterase” in 2012.As part of Green Cross’s global strategies, there are two operations based in the overseas at the moment. GC China was established in Anhui Province, China and, has produced plasma derivative products. GC China has established a pharmaceutical wholesaler last year.GCAM was established in December 2009 to secure plasma supply and enter into the US market. The company, currently runs a total of 11 plasma centers (San Bernardino, Calexico, Sacramento, Laredo, Eagle Pass, San Antonio, Leon Valley, Twin Falls, Pullman, Pasco, and Yakima), and collects 100,000 liters of plasma a year that meets FDA standards for facilities and quality and supplies it to Green Cross. GCAM will play a significant role for introducing Green Cross’s flagship products including IVIG in the US market in the near future.".
- Q16161440 foundingDate "1967-10-05".
- Q16161440 foundingYear "1967".
- Q16161440 location Q18459.
- Q16161440 location Q884.
- Q16161440 wikiPageExternalLink main.do.
- Q16161440 wikiPageWikiLink Q140686.
- Q16161440 wikiPageWikiLink Q16780075.
- Q16161440 wikiPageWikiLink Q18459.
- Q16161440 wikiPageWikiLink Q20930837.
- Q16161440 wikiPageWikiLink Q30461.
- Q16161440 wikiPageWikiLink Q7110183.
- Q16161440 wikiPageWikiLink Q8760180.
- Q16161440 wikiPageWikiLink Q884.
- Q16161440 foundation "1967-10-05".
- Q16161440 homepage "http://www.greencross.co.kr".
- Q16161440 homepage main.do.
- Q16161440 keyPeople "Byung-Geon Rhee".
- Q16161440 location Q18459.
- Q16161440 location Q884.
- Q16161440 name "Green Cross".
- Q16161440 type Organization.
- Q16161440 type Agent.
- Q16161440 type Company.
- Q16161440 type Organisation.
- Q16161440 type Agent.
- Q16161440 type SocialPerson.
- Q16161440 type Thing.
- Q16161440 type Q43229.
- Q16161440 comment "Green Cross [녹십자; 綠十字] (KRX: 006280) is a biopharmaceutical company headquartered in Yongin, South Korea.Green Cross specializes in the development and commercialization of vaccines, plasma-derivatives, recombinant proteins, and therapeutic antibodies for use in the fields of oncology and infectious disease.Green Cross was established as "Sudo Microorganism Medical Supplies Co." in 1967, and changed the name to "Green Cross" in 1971.".
- Q16161440 label "Green Cross (South Korea)".
- Q16161440 homepage www.greencross.co.kr.
- Q16161440 homepage main.do.
- Q16161440 name "Green Cross".